Literature DB >> 26341740

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Henk M Lokhorst1, Bronno van der Holt2, Jan J Cornelissen3, Marie José Kersten4, Marinus van Oers4, Reinier Raymakers5, Monique C Minnema5, Sonja Zweegman6, Gerard Bos7, Nicolaas Schaap8, Shulamiet Wittebol9, Okke de Weerdt10, Rianne Ammerlaan2, Pieter Sonneveld3.   

Abstract

Entities:  

Keywords:  allogeneic stem cell transplantation; myeloma; prognosis

Mesh：

Year:  2015        PMID： 26341740      PMCID： PMC4666343          DOI： 10.3324/haematol.2015.128728

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  The challenge of subgroup analyses--reporting without distorting.

Authors:  Stephen W Lagakos
Journal:  N Engl J Med       Date:  2006-04-20       Impact factor: 91.245

2.  Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.

Authors:  Philippe Moreau; Frédéric Garban; Michel Attal; Mauricette Michallet; Gérald Marit; Cyrille Hulin; Lotfi Benboubker; Chantal Doyen; Mohamad Mohty; Ibrahim Yakoub-Agha; Serge Leyvraz; Philippe Casassus; Hervé Avet-Loiseau; Laurent Garderet; Claire Mathiot; Jean-Luc Harousseau
Journal:  Blood       Date:  2008-11-01       Impact factor: 22.113

3.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

4.  Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Authors:  Bo Björkstrand; Simona Iacobelli; Ute Hegenbart; Astrid Gruber; Hildegard Greinix; Liisa Volin; Franco Narni; Pellegrino Musto; Meral Beksac; Alberto Bosi; Giuseppe Milone; Paolo Corradini; Hartmut Goldschmidt; Theo de Witte; Curly Morris; Dietger Niederwieser; Gösta Gahrton
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

5.  Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Damien Roos-Weil; Philippe Moreau; Hervé Avet-Loiseau; Jean-Louis Golmard; Mathieu Kuentz; Stéphane Vigouroux; Gérard Socié; Sabine Furst; Jean Soulier; Steven Le Gouill; Sylvie François; Anne Thiebaut; Agnès Buzyn; Natacha Maillard; Ibrahim Yakoub-Agha; Nicole Raus; Jean-Paul Fermand; Mauricette Michallet; Didier Blaise; Nathalie Dhédin
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

6.  International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.

Authors:  Henk Lokhorst; Hermann Einsele; David Vesole; Benedetto Bruno; Jesus San Miguel; Jose A Pérez-Simon; Nicolaus Kröger; Philippe Moreau; Gosta Gahrton; Cristina Gasparetto; Sergio Giralt; William Bensinger
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

7.  A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

Authors:  Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H van Oers; Peter von dem Borne; Pierre Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk-Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

8.  A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

Authors:  Laura Rosiñol; José Antonio Pérez-Simón; Anna Sureda; Javier de la Rubia; Felipe de Arriba; Juan José Lahuerta; José David González; Joaquín Díaz-Mediavilla; Belén Hernández; Javier García-Frade; Dolores Carrera; Angel León; Miguel Hernández; Pascual Fernández Abellán; Juan Miguel Bergua; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

9.  A comparison of allografting with autografting for newly diagnosed myeloma.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Nicola Mordini; Bernardino Allione; Fabrizio Carnevale-Schianca; Luisa Giaccone; Roberto Sorasio; Paola Omedè; Ileana Baldi; Sara Bringhen; Massimo Massaia; Massimo Aglietta; Alessandro Levis; Andrea Gallamini; Renato Fanin; Antonio Palumbo; Rainer Storb; Giovannino Ciccone; Mario Boccadoro
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

10.  Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation.

Authors:  Brent R Logan; John P Klein; Mei-Jie Zhang
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701
View more
  4 in total

1.  Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.

Authors:  Annalisa Paviglianiti; Erick Xavier; Annalisa Ruggeri; Patrice Ceballos; Eric Deconinck; Jan J Cornelissen; Stephanie Nguyen-Quoc; Natacha Maillard; Guillermo Sanz; Pierre-Simon Rohrlich; Laurent Garderet; Fernanda Volt; Vanderson Rocha; Nicolaus Kroeger; Eliane Gluckman; Nathalie Fegueux; Mohamad Mohty
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

2.  Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Christine Eisfeld; Eva Eßeling; Ramona Wullenkord; Cyrus Khandanpour; Julia Reusch; Jan-Henrik Mikesch; Christian Reicherts; Andrea Kerkhoff; Christoph Schliemann; Torsten Kessler; Rolf M Mesters; Wolfgang E Berdel; Georg Lenz; Matthias Stelljes
Journal:  Ann Hematol       Date:  2020-05-22       Impact factor: 3.673

Review 3.  Immunotherapy in myeloma: how far have we come?

Authors:  Laurens E Franssen; Tuna Mutis; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Ther Adv Hematol       Date:  2019-01-18

Review 4.  Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.

Authors:  Jean-Sébastien Claveau; Francis K Buadi; Shaji Kumar
Journal:  Oncol Ther       Date:  2022-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.